Open access
Open access
Powered by Google Translator Translator

Gastroenterology (all articles)

ACG Guideline | Diagnosis and management of biliary strictures

3 Mar, 2023 | 14:13h | UTC

ACG Clinical Guideline: Diagnosis and Management of Biliary Strictures – The American Journal of Gastroenterology

 


RCT | Effects of a vibrating capsule for chronic constipation

3 Mar, 2023 | 13:41h | UTC

Randomized Placebo-Controlled Phase 3 Trial of Vibrating Capsule for Chronic Constipation – Gastroenterology (link to abstract – $ for full-text)

Commentary: Researchers reveal the impact of vibrating capsules in chronic constipation patients – News Medical

 


Review | Platelet aggregation inhibitors and anticoagulants in gastroenterological and visceral surgical procedures

1 Mar, 2023 | 14:03h | UTC

Platelet Aggregation Inhibitors and Anticoagulants in Gastroenterological and Visceral Surgical Procedures – Deutsches Ärzteblatt international

Related: Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR)

 


Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP

1 Mar, 2023 | 13:56h | UTC

Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: a population-based, cross-sectional cohort study – Gut

 

Commentary on Twitter

 


RCT | Single CT colonography vs. three rounds of fecal immunochemical test for screening of colorectal cancer

1 Mar, 2023 | 13:43h | UTC

Single CT colonography versus three rounds of faecal immunochemical test for population-based screening of colorectal cancer (SAVE): a randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Study links proton pump inhibitor use to increased risk of acquiring drug-resistant bacteria in hospitalized patients

27 Feb, 2023 | 13:13h | UTC

Summary: This case-control study investigated whether proton pump inhibitors (PPIs) are associated with an increased risk of acquiring extended-spectrum β-lactamase (ESBL) or carbapenemase-producing Enterobacterales among hospitalized patients. The study involved 2239 adult hospitalized patients. After controlling for confounding factors, patients who received PPIs within the previous 30 days had a nearly 50% increased risk (aIRR, 1.48) of acquiring ESBL- or carbapenemase-producing Enterobacterales compared with those who did not receive PPIs. The study has the limitations of an observational study but points to the need for judicious use of PPIs to mitigate the risk of acquiring drug-resistant Enterobacterales among hospitalized patients.

Article: Association of Proton Pump Inhibitor Use With Risk of Acquiring Drug-Resistant Enterobacterales – JAMA Network Open

Commentaries:

Study links acid suppressants to colonization with multidrug-resistant bacteria – CIDRAP

Proton Pump Inhibitors Associated With Increased Risk of Drug-Resistant Infections – HCP Live

Related: Meta-Analysis: Evaluation of the Association Between Gastric Acid Suppression and Risk of Intestinal Colonization with Multidrug-Resistant Microorganisms

 


Cohort Study | Could regular laxative use be associated with an increased risk of dementia?

27 Feb, 2023 | 12:59h | UTC

Association Between Regular Laxative Use and Incident Dementia in UK Biobank Participants – Neurology (link to abstract – $ for full-text)

News Release: Study: People Who Regularly Use Laxatives May Have an Increased Risk of Dementia – American Academy of Neurology

Commentary: Regular Use of Laxatives Linked to Risk for All-Cause Dementia – HealthDay

 


Guideline | Diagnosis and treatment of Helicobacter pylori

24 Feb, 2023 | 13:53h | UTC

Helicobacter pylori World Gastroenterology Organization Global Guideline – Journal of Clinical Gastroenterology

Related:

AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review – Gastroenterology

Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020 – The Korean Journal of Internal Medicine

Management of Helicobacter pylori infection: Guidelines of the Italian Society of Gastroenterology (SIGE) and the Italian Society of Digestive Endoscopy (SIED) – Digestive and Liver Disease

 


M-A | Efficacy of elimination diets in eosinophilic esophagitis

24 Feb, 2023 | 13:47h | UTC

Summary: This systematic review and meta-analysis evaluated the effectiveness of various dietary treatment regimens for eosinophilic esophagitis (EoE). After analyzing 34 studies with 1762 patients, it was concluded that dietary therapy is a viable and efficacious option for individuals with EoE of all ages, with an overall histological remission rate of 53.8% and a clinical response rate of 80.8%. The study also found that highly restrictive dietary regimes, such as a six-food elimination diet, may not be superior to less restrictive dietary regimens, such as a four-food elimination diet or one-food elimination diet, in achieving histological remission, supporting less restrictive dietary regimens as a treatment option. The study has several limitations, such as the observational nature of most studies included.

Article: Efficacy of elimination diets in eosinophilic esophagitis: a systematic review and meta-analysis – Clinical Gastroenterology and Hepatology

Commentary: Elimination diets effective for patients with eosinophilic esophagitis – ACP Gastroenterology

 

Commentary on Twitter

Article under a Creative Commons Attribution (CC BY 4.0) license

 


RCT | Electroacupuncture may improve opioid-induced constipation in patients with cancer

24 Feb, 2023 | 13:46h | UTC

Summary: The study was a randomized clinical trial that evaluated the efficacy and safety of electroacupuncture (EA) for opioid-induced constipation (OIC) in adult patients with cancer pain. The trial included 100 patients with cancer and OIC who were randomly assigned to receive either EA or sham electroacupuncture (SA) for 24 sessions over 8 weeks. The study found that the proportion of overall responders was greater with EA (40,1%) than with SA (9,0%) at week 8, suggesting that EA treatment could be a safe and effective alternative for managing OIC in adult cancer patients. However, the trial’s limitations, such as the wide heterogeneity of cancer patients, the self-reported diary measurements, and the inability to blind acupuncturists, should be considered. Additionally, it’s worth noting that more patients in the EA group guessed that they received actual EA treatment compared to those who received SA (46 vs 22 patients).

Article: Effects of Electroacupuncture for Opioid-Induced Constipation in Patients With Cancer in China: A Randomized Clinical Trial – JAMA Network Open

 

Commentary on Twitter

 


Review | Constipation in children and adolescents

23 Feb, 2023 | 13:06h | UTC

Constipation in Children and Adolescents – Deutsches Ärzteblatt international

 


AGA Guideline | Role of biomarkers for the management of ulcerative colitis

22 Feb, 2023 | 12:38h | UTC

AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis – Gastroenterology

News Release: New AGA guideline recommends blood and stool tests for monitoring ulcerative colitis – American Gastroenterological Association

 


AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease

22 Feb, 2023 | 12:37h | UTC

AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease – Hepatology

Related:

Management of NAFLD in primary care settings – Liver International

Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – Zeitschrift für Gastroenterologie

AGA Clinical Practice Update | Diagnosis and management of nonalcoholic fatty liver disease in lean individuals.

Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group – The Lancet Gastroenterology & Hepatology (free registration required)

Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association – Arteriosclerosis, Thrombosis, and Vascular Biology

Advancing the global public health agenda for NAFLD: a consensus statement – Nature Reviews Gastroenterology & Hepatology

Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease – Gastroenterology

Non-alcoholic fatty liver disease: A patient guideline – JHEP Reports

 


RCT | Cold snare polypectomy reduces bleeding compared to hot snare polypectomy

22 Feb, 2023 | 12:34h | UTC

Cold Versus Hot Snare Polypectomy for Small Colorectal Polyps: A Pragmatic Randomized Controlled Trial – Annals of Internal Medicine (link to abstract – $ for full-text)

News Release: Cold snare polypectomy significantly reduces bleeding risk compared to hot snare polypectomy – Science News Net

 


SR | Probiotics for management of functional abdominal pain disorders in children

22 Feb, 2023 | 12:20h | UTC

Probiotics for management of functional abdominal pain disorders in children – Cochrane Library

 


RCT | Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease

20 Feb, 2023 | 12:27h | UTC

Summary: The article reports on a randomized trial that compared the effects of alternate-day fasting (ADF) combined with exercise, fasting alone, or exercise alone in adults with obesity and non-alcoholic fatty liver disease (NAFLD). After three months, the combination of ADF and exercise significantly reduced intrahepatic triglyceride content, body weight, fat mass, waist circumference, and alanine transaminase levels compared to the control group. The intervention seems promising for patients with fatty liver disease who want to improve their health without using medications.

Article: Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial – Cell Metabolism (link to abstract – $ for full-text)

News Release: Alternate-day fasting could be a good option for patients with fatty liver disease – University of Illinois Chicago

 


M-A | Efficacy and safety of drugs for gastroparesis

17 Feb, 2023 | 13:05h | UTC

Efficacy and Safety of Drugs for Gastroparesis: Systematic Review and Network Meta-analysis – Gastroenterology

Commentaries:

Review finds only two efficacious medications to treat gastroparesis – ACP Gastroenterology

Two drug classes appear effective for gastroparesis treatment – MDedge

 

Commentary from the author on Twitter (thread – click for more)

 


Review | Perioperative optimization of Crohn’s disease

17 Feb, 2023 | 12:39h | UTC

Perioperative optimization of Crohn’s disease – Annals of Gastroenterological Surgery

 


Current status of liver transplantation for non-B non-C liver cirrhosis and hepatocellular carcinoma

17 Feb, 2023 | 12:36h | UTC

Current status of liver transplantation for non-B non-C liver cirrhosis and hepatocellular carcinoma – Annals of Gastroenterological Surgery

 


Rare, overlooked, or underappreciated causes of recurrent abdominal pain: a primer for gastroenterologists

16 Feb, 2023 | 15:12h | UTC

Rare, Overlooked, or Underappreciated Causes of Recurrent Abdominal Pain: A Primer for Gastroenterologists – Clinical Gastroenterology and Hepatology

 

Commentary from the author on Twitter

 


RCT | Orlistat and a low-carb diet show promising results for the treatment of Metabolic-Associated Fatty Liver Disease

16 Feb, 2023 | 15:07h | UTC

Summary: The study aimed to compare the effects of orlistat or a high-protein/lower-carbohydrate diet with a control diet in Asian patients with obesity and metabolic-associated fatty liver disease (MAFLD) over 24 weeks. The primary endpoint was the relative change in liver fat content (LFC) assessed by MRI-PDFF. A total of 118 patients were randomly assigned to the control group, orlistat group, or experimental diet group. All three groups demonstrated improvement in liver steatosis at week 24, with the orlistat group and the experimental diet group both showing a significant decrease in LFC compared to the control group.*

Article: Treatment of Obesity and Metabolic-Associated Fatty Liver Disease with a Diet or Orlistat: A Randomized Controlled Trial – American Journal of Clinical Nutrition

Commentary: The efficiency of lifestyle intervention, orlistat, and experimental diet therapy in patients with obesity and metabolic-associated fatty liver disease – News Medical

 

*Note: This summary was created through the collaboration of a medical editor and ChatGPT.

 


Cohort Study | Antibiotics, hormonal therapies, oral contraceptives, and NSAIDS linked to increased risk of inflammatory bowel disease

16 Feb, 2023 | 14:59h | UTC

Associations of Antibiotics, Hormonal Therapies, Oral Contraceptives, and Long-Term NSAIDS With Inflammatory Bowel Disease: Results From the Prospective Urban Rural Epidemiology (PURE) Study – Clinical Gastroenterology and Hepatology (link to abstract – $ for full-text)

Commentary: Antibiotics, hormonal medications, oral contraceptives, and long-term NSAID tied with IBD – Medical Dialogues

 


Position Paper | Medical Management of pediatric inflammatory bowel disease

15 Feb, 2023 | 16:03h | UTC

Medical Management of Pediatric Inflammatory Bowel Disease (PIBD) in the Asia Pacific Region: A Position Paper by the Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group – Journal of Gastroenterology and Hepatology

 


Single-arm study | Effects of SER-109 as an investigational microbiome therapeutic in recurrent C. difficile infection

14 Feb, 2023 | 10:47h | UTC

Summary: This was a phase 3, open-label, single-arm trial of 263 adults with recurrent Clostridioides difficile Infection (CDI). The trial aimed to evaluate the safety and rate of CDI recurrence after administration of the investigational microbiome therapeutic SER-109. The trial found that SER-109 was well tolerated and the overall rate of recurrent CDI was low, regardless of the number of prior recurrences, demographics, or diagnostic approach.

(By ChatGPT, reviewed and edited)

 

Article: Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial – JAMA Network Open

Commentary: Phase 3 trial provides more positive data for recurrent C diff microbiome drug – CIDRAP

Related:

RCT: Among patients with recurrent Clostridioides difficile infection, the use of SER-109, an oral microbiome therapy, reduced recurrence rate compared to placebo (12% vs. 40%).

Post-trial follow-up | Microbiome therapeutic SER-109 through 24 weeks for recurrent Clostridioides difficile infection.

 


Guideline | Barrett’s esophagus and stage 1 esophageal adenocarcinoma: monitoring and management

13 Feb, 2023 | 12:49h | UTC

Barrett’s oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management – National Institute for Health and Care Excellence

Related: Diagnosis and Management of Barrett’s Esophagus: An Updated ACG Guideline – American Journal of Gastroenterology

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.